繁體
简体中文
繁體中文

Vaxcyte, Inc. PCVX 深 滬

交易中 11-18 10:59:19 美东时间

58.115

-1.285

-2.16%

华盛通華盛通
立即下載
  • 最 高62.59
  • 今 開59.16
  • 成交量 22.39万股
  • 最 低 57.60
  • 昨 收 59.40
  • 總市值 338.89万
  • 52周最高 90.75
  • 市盈率 靜 --
  • 換手率 384.00%
  • 52周最低 42.40
  • 委 比 -93.55%
  • 總股本 5.83万
  • 歷史最高 121.055
  • 量 比 1.39
  • 振 幅 8.40%
  • 歷史最低 1.10
  • 每 手 1
  • 風險率 6.17%

個股概要

財務分析

公司資料

相關新聞

分紅派息

  • 分時圖
  • 日k
  • 周k
  • 月k

相關新聞

更多
  • 高“价”疫苗,来了

    本月,美国药企Vaxcyte公布了旗下31价肺炎球菌结合疫苗VAX-31的一项临床试验结果:全部预设主要终点达成。 消息公布当日,该公司股价涨超30%,市值一度...

    10-28 11:08

  • 10 Health Care Stocks With Whale Alerts In Today’s Session

    This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often

    06-30 01:35

  • Earnings Outlook For Vaxcyte

    Vaxcyte (NASDAQ:PCVX) is preparing to release its quarterly earnings on Tuesday...

    02-24 00:01

  • Vaxcyte shares are trading lower after the company announced a $500 million offering.

    Vaxcyte shares are trading lower after the company announced a $500 million off...

    01-30 05:29

  • Vaxcyte Pushes Next-Gen Pneumococcal Vaccine Into Phase 3 Phase

    Vaxcyte shares rise after starting Phase 3 trials for its VAX-31 pneumonia vaccine, expanding studies in adults and infants while planning major U.S. manufacturing investments.

    01-23 23:12

  • CDC专家组支持扩大肺炎球菌疫苗接种年龄 辉瑞默沙东市场大扩容

    美国疾病控制与预防中心(CDC)的免疫实践咨询委员会(ACIP)以14比1的投票结果推荐将肺炎球菌结合疫苗(PCV)的接种年龄建议降低至50岁及以上的成年人,这一决策可能显著扩大辉瑞(PFE.US)和默沙东(MRK.US)的疫苗市场。此前,CDC的建议是65岁以上的成年人和5岁以下的儿童接种肺炎球菌疫苗,同时建议某些免疫功能低下的群体接种。两家公司均请求CDC降低年龄建议至50岁以上的成年人。 这一建议得到了CDC主任曼迪·科恩的认可,她之前对肺炎球菌疫苗的指导主要集中在65岁以上的成年人和5岁以下的儿童。辉瑞和默沙东都希望这一变更能够增加他们的疫苗销售额。辉瑞的Prevnar是其最畅销的产品...

    2024-10-24 15:15

  • B of A Securities Maintains Buy on Vaxcyte, Raises Price Target to $140

    B of A Securities analyst Jason Gerberry maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price target from $101 to $140.

    2024-09-04 19:34

  • Vaxcyte Starts $1 Billion Underwritten Public Offering

    04:35 PM EDT, 09/03/2024 (MT Newswires) -- Vaxcyte (PCVX) said Tuesday it started a $1 billion underwritten public offering of common shares and pre-funded warrants. The company said it plans to give underwriters a 30-day option to buy up to an additional $150 million of common shares, including tho...

    2024-09-04 04:35

  • Sector Update: Health Care Stocks Decline Late Afternoon

    04:00 PM EDT, 09/03/2024 (MT Newswires) -- Health care stocks fell late Tuesday afternoon with the NYSE Health Care Index shedding 0.5% and the Health Care Select Sector SPDR Fund (XLV) down 0.3%. The iShares Biotechnology ETF (IBB) dropped 1.8%. In corporate news, TC BioPharm (TCBP) shares jumped 2...

    2024-09-04 04:00

  • Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

    Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) dipped 11.6% to $6.43. The company on Tuesday announced Phase 2 data for an investigational treatment for symptomatic Cerebral Cavernous Malformation (CCM). Nikola shares dipped 10.4% to $7.28 on Monday. Here are some other stocks moving in tod...

    2024-09-04 01:41